A randomised comparison of ganirelix and cetrorelix use in ICSI cycle of women with polycystic ovary syndrome

Küçük Resim Yok

Tarih

2007

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Elsevier

Erişim Hakkı

CC0 1.0 Universal
info:eu-repo/semantics/openAccess

Araştırma projeleri

Organizasyon Birimleri

Dergi sayısı

Özet

OBJECTIVE: To compare the ICSI outcome of two multidose gonadotropin releasing hormone antagonist (GnRH-ant) in women with polycystic ovary syndrome (PCOS). DESIGN: A prospective, randomized, single-blind study in a referral center for assisted reproduction. MATERIALS AND METHODS: Eighty two women with the diagnosis of PCOS were randomly assigned to either multidose ganirelix or multidose cetrorelix, started when the dominant follicle has reached >13 mm in diameter. The sample size calculation was based on an average of 36% clinical pregnancy rate. To find a 16% change in the clinical pregnancy rate with a power of 0.80 at a ¼ 0.05, the total sample size required was 71 women. In order to achieve adequate sample size after cycle cancellation 82 women were recruited in the study. Chi-square and student-t test were used as appropriate. RESULTS: The mean age, the body mass index, infertility period, cleavage rate, fertilisation rates were similar in the two groups (P>0.05). The cycle cancellation rate was 14.6% in the ganirelix group and 12.2% in the cetrorelix group (P¼0.07). The number of good quality embryos obtained was 2.8 0.6 in the ganirelix group while it was 2.6 0.5 in the cetrorelix group. The clinical pregnancy rate was 40% in the ganirelix group and 30.6% in the cetrorelix group (P¼0.4). Take home baby rate were 31.4% in the ganirelix group and 22.2% in the cetrorelix group (P¼0.38). CONCLUSIONS: The two GnRH-ant were found to have similar ICSI outcomes in PCOS patients.

Açıklama

Anahtar Kelimeler

Kaynak

Fertility and Sterility

WoS Q Değeri

Scopus Q Değeri

Q1

Cilt

88

Sayı

Künye

Kars, B., Sofuoğlu, K., Çalışkan, E., Öztekin, D. C., Aktaş, R. G. ve Tuğ, N. (2007). A randomised comparison of ganirelix and cetrorelix use in ICSI cycle of women with polycystic ovary syndrome. Fertility and Sterility, Elsevier. 88, s. 181.